Noubar Afeyan, Ph.D., is Co-Founder and Chairman of Tessera Therapeutics and Founder and CEO of Flagship Pioneering. Its research engine further optimizes the discovered candidates for efficiency, specificity, and fidelity-essentially compressing eons of evolution into a few months. Tessera Therapeutics are the innovators behind Gene Writing and Gene Rewriting, new biotechnologies designed to offer scientists and clinicians the ability to. The company has evaluated tens of thousands of natural and synthetic MGEs to create candidates with the ability to write therapeutic messages into the human genome. Tessera’s gene writer tools are based on nature’s genome architects, Mobile Genetic Elements (MGEs)-the most abundant class of genes across the tree of life, representing approximately half of the human genome. Jun 28 10 years ago, the first publication on the gene-editing tech CRISPR changed the field.The platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Led by Geoffrey von Maltzahn, Ph.D., Co-Founder, Chief Executive Officer, and Board Director, Tessera Therapeutics provides gene writing technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. Disability Disability Veteran Status Want more demographic options Non-disabled (5) 3.4 People with Disabilities 5. The company intends to use the funds to expand its development efforts. This rating reflects the overall rating of Tessera Therapeutics and is not affected by filters. Investors included Abu Dhabi Investment Authority (ADIA), Alaska Permanent Fund Corporation, Altitude Life Science Ventures, ARTIS Ventures, Cormorant Asset Management, Flagship Pioneering, Hanwha Impact Partners, Longevity Vision Fund, March Capital, SALT Fund, SoftBank Vision Fund 2, and T. ![]() Tessera Therapeutics, a Somerville, MA-based biotechnology company, raised over $300M in Series C funding.
0 Comments
Leave a Reply. |